Healthcare ACtive Runners: Teva Pharmaceutical Industries (NYSE:TEVA), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX), Abbott Laboratories (NYSE:ABT), Celgene (NASDAQ:CELG)

Just a month ago, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) snapped up portfolio company, San Mateo, CA-based Labrys Biologics, for $200 million up front and another $625 million in milestones. That deal came less than two years after Labrys was formed, and venBio partner and co-founder Corey Goodman told Xconomy at the time that venBio had contributed $8.5 million of Labrys’ $31 million Series A round plus an “extra kicker” for putting the deal together. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was 1.61% in last session and finished the day at $54.42. Traded volume was 4.88million shares in the last session and the average volume of the stock remained 5.36million shares. The beta of the stock remained 0.67.

Exelixis Inc (NASDAQ:EXEL) was the recipient of a significant decrease in short interest in the month of June. As of June 13th, there was short interest totalling 48,357,190 shares, a decrease of 1.5% from the May 30th total of 49,073,148 shares. Exelixis, Inc. (NASDAQ:EXEL) rose 4.65 percent to $3.60 Wednesday on volume of 4.92million shares. The intra-day range of the stock was $3.44 to $3.65. Exelixis, Inc. (NASDAQ:EXEL) has a market capitalization of $700.90million.

Earlier in June, Novavax Inc. (NASDAQ:NVAX) announced a $100 million secondary offering of common stock. The underwriters are JPMorgan (JPM) and Citibank (C) , two global investment banks that currently do not cover the stock from a research standpoint. Novavax, Inc. (NASDAQ:NVAX)’s stock on July 02, 2014 reported a increase of 3.09% to the closing price of $5.01. Its fifty two weeks range is $2.09 -$6.95. The total market capitalization recorded $1.19billion. The overall volume in the last trading session was 5.31million shares. In its share capital, NVAX has 234.31million outstanding shares.

Abbott Laboratories (NYSE:ABT) continues to lead the investment trend in emerging nations with about 50% of sales coming in from this market. The company expects this contribution to climb to 60% by 2015. On Wednesday, shares of Abbott Laboratories (NYSE:ABT) advanced 1.48% to close the day at $41.79. Company return on investment (ROI) is 8.00% and its monthly performance is recorded as 4.95%. Abbott Laboratories (NYSE:ABT) quarterly revenue growth is 8.97%.

GlobeImmune has inked collaboration agreements with Gilead Sciences Inc., for a drug to treat chronic hepatitis B virus, and with Celgene Corp. (NASDAQ:CELG), for oncology products. Those two partnerships have combined for more than $60 million in revenue for GlobeImmune as of March 31, according to a filing made Monday with the U.S. Securities and Exchange Commission. Celgene Corporation (NASDAQ:CELG) stock performance was 1.77% in last session and finished the day at $90.07. Traded volume was 5.94million shares in the last session and the average volume of the stock remained 5.95million shares. The beta of the stock remained 1.15. Celgene Corporation (NASDAQ:CELG) insider ownership is 0.20%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone